羅妥木單抗

化合物

羅妥木單抗INN:Robatumumab;開發代號:SCH 717454MK-7454)是默克先靈葆雅生產的單克隆抗體抗腫瘤藥物。它與CD221(或稱胰島素樣生長因子1受體)結合。[1]

羅妥木單抗
單克隆抗體
種類完整抗體
目標CD221
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號934235-44-6  ☒N
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6418H9960N1732O1992S42
摩爾質量144,602.93 g·mol−1

針對結直腸癌骨肉瘤尤文氏肉瘤患者的II期臨床試驗已經完成。[2][3]此後默克公司停止了該藥物的開發。[4]

參考資料

編輯
  1. ^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines. Encrenaz C , 編. Proposed International Nonproprietary Names: List 100 (PDF). WHO Drug Information. 2008, 22 (4): 311–67 [2024-01-24]. (原始內容存檔 (PDF)於2022-01-20). 
  2. ^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer. October 2016, 63 (10): 1761–70. PMC 5129487 . PMID 27362300. doi:10.1002/pbc.26087. 
  3. ^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
  4. ^ Robatumumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-24]. (原始內容存檔於2024-01-24).